Evidence map›Paper›PMID 21274879›Full record

ArticleHepatology (Baltimore, Md.)2011

Excessive hepatomegaly of mice with hepatocyte-targeted elimination of integrin linked kinase following treatment with 1,4-bis [2-(3,5-dichaloropyridyloxy)] benzene.

Shashikiran Donthamsetty, Vishakha S Bhave, Corrine S Kliment, William C Bowen, Wendy M Mars, Aaron W Bell, Rachel E Stewart, Anne Orr, Chuanyue Wu, George K Michalopoulos

RetractedErratum issuedOpen access · bronzeAbstract read
In one paragraph

Article in Hepatology (Baltimore, Md.), 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 30 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Elucidating the metabolic regulation of liver regeneration.The American journal of pathology · 2014
    Review
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Shashikiran DonthamsettyDepartment of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15261, USA.
Vishakha S Bhave
Corrine S Kliment
William C Bowen
Wendy M Mars
Aaron W Bell
Rachel E Stewart
Anne Orr
Chuanyue Wu
George K Michalopoulos
University of Pittsburgh · US

Funding

HGF IN LIVER REGENERATION, DIFFERENTIATION AND NEOPLASIAR01CA035373 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI MICHALOPOULOS, GEORGE K · 1985 to 2011
$3.8M
HGF and Signaling Pathways in Hepatic Tissue AssemblyR01CA103958 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI MICHALOPOULOS, GEORGE K · 2004 to 2014
$2.9M
HGF AND HEPATOCYTES IN NEOPLASIA AND LIVER FAILURER37CA030241 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI MICHALOPOULOS, GEORGE K · 1994 to 2001
$578k
NCI NIH HHS 5R01CA035373-26NCI NIH HHS R01 CA035373NCI NIH HHS R01 CA103958NCI NIH HHS R37 CA030241
6 · The paper itself

Abstract

unlabelledTCBOPOP (1,4-bis [2-(3,5-dichaloropyridyloxy)] benzene) an agonist of the constitutive androstane receptor (CAR), produces rapid hepatocyte hyperplasia and hepatomegaly in the absence of hepatic injury. In this study we demonstrate that integrin-linked kinase (ILK), which is involved in transmission of the extracellular matrix (ECM) signaling by way of integrin receptors, plays an important role in regulating TCPOBOP-induced proliferation of hepatocytes and hepatomegaly. Hepatocyte-specific ILK knockout mice (ILK/liver-/- mice) and wildtype mice (WT) were given a single dose of TCPOBOP (3 mg/kg) by oral gavage. Mice were sacrificed at days 1, 2, 5, and 7 after TCPOBOP administration. WT mice showed maximum proliferation on days 1 and 2, which came back to baseline levels by days 5 and 7 after TCPOBOP administration. The ILK/liver-/- mice, on the other hand, showed a prolonged and a sustained proliferative response as evident by an increased number of proliferative cell nuclear antigen assay (PCNA)-positive cells even at days 5 and 7 after TCPOBOP administration. At day 7 the WT mice showed close to a 2.5-fold increase in liver weight, whereas the ILK/liver-/- mice showed a 3.7-fold increase in liver weight. The prolonged proliferative response in the ILK/liver-/- mice seems to be due to sustained induction of CAR leading to sustained induction of c-Myc, which is known to be a key mediator of TCPOPOP-CAR induced direct liver hyperplasia.

conclusionThe data indicate that ECM-mediated signaling by way of ILK is essential for adjustment of final liver size and proper termination of TCPOBOP-induced proliferation of hepatocytes.

Indexed as

AnimalsBody WeightCell CycleCell ProliferationDisease Models, AnimalExtracellular MatrixHepatocytesHepatomegalyMiceMice, KnockoutOrgan SizeProtein Serine-Threonine KinasesProto-Oncogene Proteins c-mycPyridinesScaffold Protein ILKSignal Transduction1,4-bis(2-(3,5-dichloropyridyloxy))benzeneProtein Serine-Threonine KinasesProto-Oncogene Proteins c-mycPyridinesScaffold Protein ILK

Identifiers

PMID21274879
PMCPMC3062106
OpenAlexW2039088913

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.